ES2712652T3 - Procesos para la preparación de (S)-3-4-((4-(morfolinometil) bencil) oxi) -1-oxoisoindolin-2il-) piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas - Google Patents
Procesos para la preparación de (S)-3-4-((4-(morfolinometil) bencil) oxi) -1-oxoisoindolin-2il-) piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas Download PDFInfo
- Publication number
- ES2712652T3 ES2712652T3 ES13753229T ES13753229T ES2712652T3 ES 2712652 T3 ES2712652 T3 ES 2712652T3 ES 13753229 T ES13753229 T ES 13753229T ES 13753229 T ES13753229 T ES 13753229T ES 2712652 T3 ES2712652 T3 ES 2712652T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- compound
- substituted
- enantiomerically
- pure compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 NC(C(CCC([N+]([O-])=O)=O)*(Cc1c2cccc1OCc1ccc(C*3CCOCC3)cc1)C2=O)=O Chemical compound NC(C(CCC([N+]([O-])=O)=O)*(Cc1c2cccc1OCc1ccc(C*3CCOCC3)cc1)C2=O)=O 0.000 description 2
- IXZOHGPZAQLIBH-UHFFFAOYSA-N O=C(c1cccc(OCc2ccc(CN3CCOCC3)cc2)c1C1)N1C(CCC(N1)=O)C1=O Chemical compound O=C(c1cccc(OCc2ccc(CN3CCOCC3)cc2)c1C1)N1C(CCC(N1)=O)C1=O IXZOHGPZAQLIBH-UHFFFAOYSA-N 0.000 description 1
- MWVQMAWLNHACQK-UHFFFAOYSA-N OCc1ccc(CN2CCOCC2)cc1 Chemical compound OCc1ccc(CN2CCOCC2)cc1 MWVQMAWLNHACQK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681477P | 2012-08-09 | 2012-08-09 | |
| PCT/US2013/054099 WO2014025978A1 (en) | 2012-08-09 | 2013-08-08 | Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2712652T3 true ES2712652T3 (es) | 2019-05-14 |
Family
ID=49035933
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13753229T Active ES2712652T3 (es) | 2012-08-09 | 2013-08-08 | Procesos para la preparación de (S)-3-4-((4-(morfolinometil) bencil) oxi) -1-oxoisoindolin-2il-) piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas |
| ES18206764T Active ES2914876T3 (es) | 2012-08-09 | 2013-08-08 | Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18206764T Active ES2914876T3 (es) | 2012-08-09 | 2013-08-08 | Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9309220B2 (enExample) |
| EP (2) | EP3466942B1 (enExample) |
| JP (1) | JP6444866B2 (enExample) |
| KR (1) | KR20150041650A (enExample) |
| CN (1) | CN104718202B (enExample) |
| AU (1) | AU2013299559B2 (enExample) |
| BR (1) | BR112015002183A2 (enExample) |
| CA (2) | CA2879151C (enExample) |
| CR (1) | CR20150051A (enExample) |
| EC (1) | ECSP15004585A (enExample) |
| ES (2) | ES2712652T3 (enExample) |
| HK (1) | HK1211577A1 (enExample) |
| IL (1) | IL236925A0 (enExample) |
| IN (1) | IN2015DN00845A (enExample) |
| MX (2) | MX2015001633A (enExample) |
| PH (1) | PH12015500214A1 (enExample) |
| RU (1) | RU2015108057A (enExample) |
| SG (1) | SG11201500984QA (enExample) |
| WO (1) | WO2014025978A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201501062SA (en) | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| EP2968334A4 (en) | 2013-03-14 | 2016-08-03 | Deuterx Llc | 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| JP7399846B2 (ja) | 2017-08-21 | 2023-12-18 | セルジーン コーポレイション | （ｓ）－ｔｅｒｔ－ブチル４，５－ジアミノ－５－オキソペンタノエートの調製プロセス |
| AU2019351811B2 (en) | 2018-10-01 | 2025-01-02 | Celgene Corporation | Combination therapy for the treatment of cancer |
| CN110194760B (zh) * | 2019-05-27 | 2021-08-17 | 浙江农林大学暨阳学院 | 制备3-亚苄基-2-（7’-喹啉）-2,3-二氢-异吲哚-1-酮类化合物的方法 |
| CA3159978A1 (en) * | 2019-12-02 | 2021-06-10 | Celgene Corporation | Therapy for the treatment of cancer |
| CN113896711A (zh) | 2020-07-06 | 2022-01-07 | 北京诺诚健华医药科技有限公司 | 杂环类免疫调节剂 |
| WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| CN121002005A (zh) * | 2023-04-11 | 2025-11-21 | 上海科胜药物研发有限公司 | 一种芳基甲氧基异吲哚啉衍生物的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| EP2479172B1 (en) | 2004-09-03 | 2013-10-09 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
| CA2612612C (en) * | 2005-06-30 | 2014-03-11 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
| EP2142534B1 (en) | 2007-03-20 | 2016-08-10 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| SG10201501062SA (en) * | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2011111053A1 (en) | 2010-03-08 | 2011-09-15 | Natco Pharma Limited | Anhydrous lenalidomide form-i |
| ES2671608T3 (es) | 2012-02-21 | 2018-06-07 | Celgene Corporation | Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona |
-
2013
- 2013-08-08 WO PCT/US2013/054099 patent/WO2014025978A1/en not_active Ceased
- 2013-08-08 EP EP18206764.5A patent/EP3466942B1/en active Active
- 2013-08-08 CA CA2879151A patent/CA2879151C/en active Active
- 2013-08-08 CA CA3108974A patent/CA3108974C/en active Active
- 2013-08-08 SG SG11201500984QA patent/SG11201500984QA/en unknown
- 2013-08-08 ES ES13753229T patent/ES2712652T3/es active Active
- 2013-08-08 KR KR20157006015A patent/KR20150041650A/ko not_active Abandoned
- 2013-08-08 EP EP13753229.7A patent/EP2882736B1/en active Active
- 2013-08-08 MX MX2015001633A patent/MX2015001633A/es active IP Right Grant
- 2013-08-08 BR BR112015002183A patent/BR112015002183A2/pt not_active IP Right Cessation
- 2013-08-08 RU RU2015108057A patent/RU2015108057A/ru unknown
- 2013-08-08 JP JP2015526698A patent/JP6444866B2/ja active Active
- 2013-08-08 ES ES18206764T patent/ES2914876T3/es active Active
- 2013-08-08 HK HK15112292.3A patent/HK1211577A1/xx unknown
- 2013-08-08 AU AU2013299559A patent/AU2013299559B2/en active Active
- 2013-08-08 MX MX2018012684A patent/MX385058B/es unknown
- 2013-08-08 CN CN201380052461.7A patent/CN104718202B/zh active Active
- 2013-08-08 IN IN845DEN2015 patent/IN2015DN00845A/en unknown
- 2013-08-08 US US13/962,764 patent/US9309220B2/en active Active
-
2015
- 2015-01-26 IL IL236925A patent/IL236925A0/en unknown
- 2015-01-30 PH PH12015500214A patent/PH12015500214A1/en unknown
- 2015-02-05 CR CR20150051A patent/CR20150051A/es unknown
- 2015-02-06 EC ECIEPI20154585A patent/ECSP15004585A/es unknown
-
2016
- 2016-03-02 US US15/058,976 patent/US9975872B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104718202B (zh) | 2018-11-20 |
| EP3466942A1 (en) | 2019-04-10 |
| IN2015DN00845A (enExample) | 2015-06-12 |
| HK1211577A1 (en) | 2016-05-27 |
| WO2014025978A1 (en) | 2014-02-13 |
| BR112015002183A2 (pt) | 2017-07-04 |
| ES2914876T3 (es) | 2022-06-17 |
| PH12015500214A1 (en) | 2015-04-27 |
| RU2015108057A (ru) | 2016-09-27 |
| AU2013299559A1 (en) | 2015-02-05 |
| ECSP15004585A (es) | 2015-12-31 |
| JP6444866B2 (ja) | 2018-12-26 |
| MX385058B (es) | 2025-03-14 |
| CA3108974A1 (en) | 2014-02-13 |
| US20160251333A1 (en) | 2016-09-01 |
| IL236925A0 (en) | 2015-03-31 |
| CA2879151A1 (en) | 2014-02-13 |
| US20140046058A1 (en) | 2014-02-13 |
| US9975872B2 (en) | 2018-05-22 |
| AU2013299559B2 (en) | 2017-08-17 |
| CN104718202A (zh) | 2015-06-17 |
| CR20150051A (es) | 2015-05-11 |
| EP2882736B1 (en) | 2019-01-09 |
| CA2879151C (en) | 2021-03-30 |
| CA3108974C (en) | 2023-04-04 |
| SG11201500984QA (en) | 2015-04-29 |
| MX2015001633A (es) | 2015-04-08 |
| KR20150041650A (ko) | 2015-04-16 |
| JP2015524481A (ja) | 2015-08-24 |
| US9309220B2 (en) | 2016-04-12 |
| EP2882736A1 (en) | 2015-06-17 |
| EP3466942B1 (en) | 2022-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2712652T3 (es) | Procesos para la preparación de (S)-3-4-((4-(morfolinometil) bencil) oxi) -1-oxoisoindolin-2il-) piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas | |
| JP7658912B2 (ja) | 殺微生物性オキサジアゾール誘導体の調製方法 | |
| CA2971357A1 (en) | Amido thiadiazole derivatives as nadph oxidase inhibitors | |
| KR20250002239A (ko) | 치환된 스피로옥스인돌 유도체의 제조 방법 | |
| JP2018535260A (ja) | キナーゼ阻害剤およびその中間体の調製方法 | |
| AU2016382036B2 (en) | Ointment | |
| CA2880299A1 (en) | Process for the synthesis of substituted urea compounds | |
| JP7399846B2 (ja) | （ｓ）－ｔｅｒｔ－ブチル４，５－ジアミノ－５－オキソペンタノエートの調製プロセス | |
| ES2641258T3 (es) | Compuesto heterocíclico bicíclico | |
| JP2016522240A (ja) | ＲＯＲｃモジュレーターとしてのアリールスルタム誘導体 | |
| ES2791187T3 (es) | Síntesis de dabigatrán | |
| DK174867B1 (da) | 1,4-Dihydropyridinderivater, farmaceutiske præparater deraf, anvendelse af forbindelserne til fremstilling af sådanne præparater og fremgangsmåde til fremstilling af forbindelserne | |
| JP2007522213A (ja) | 置換されたトリアゾール化合物の製造方法 | |
| WO2019145360A1 (en) | Novel compounds for the treatment of parasitic infections | |
| JP4538237B2 (ja) | Ｃｃｒ５アンタゴニストとしてのピペリジン化合物およびピペラジン化合物の合成 |